BioSpace News Archive

Invitae (NYSE: NVTA), a leading medical genetics company, today announced the launch of the Rare Patient Network expanding Invitae’s Ciitizen platform to all patients with pediatric epilepsy and/or developmental delay with plans to include other conditions in the coming months.

Mind Medicine today announced that members of the Company’s management team will participate in Canaccord Genuity’s New Paradigms and Treatment Approaches in Mental Health Conference.

Pfizer Inc. and Valneva SE reported antibody persistence data six months after the completion of a three-dose or a two-dose vaccination schedule with their Lyme disease vaccine candidate, VLA15 in both children and adults.

Innate Pharma SA announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O Annual Congress in Geneva, Switzerland.

France’s Gustave Roussy Institute, Europe’s leading cancer center and ranked third in the world according to Newsweek Magazine, has chosen to partner with Synapse Medicine, a leader in clinical pharmacy and medication reconciliation.

Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA -based therapeutics for patients with cardiac diseases, announced that Orly Vardeny, PharmD, MS, joins its Board of Directors as a permanent guest.

Kineta, Inc. announced that the Company will present at the Antibody Engineering and Therapeutics Conference, the Antibody Society’s Annual Meeting, to be held in-person in San Diego, CA from December 4-8, 2022.

Catheter Precision, Inc. announces that more than 800 procedures have been performed in a number of leading U.S. and European hospitals utilizing the VIVO System that enables physicians to noninvasively identify an area of ventricular arrhythmia onset.

Merck, known as MSD outside of the United States and Canada, announced the presentation of findings from clinical trials and real-world studies at the upcoming 64th American Society of Hematology Annual Meeting from Dec. 10-13, 2022, in New Orleans, Louisiana and virtually.

RetinAI Medical AG (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence in Ophthalmology, is proud to launch Discovery CORE™ with AI for retinal fluid and layer segmentation. Discovery CORE and its AI models have been designed to accelerate data analysis and help clinical and academic researchers collaborate more efficiently, in real time, with their peers, on medical and imaging datasets.